- Previous Close
41.17 - Open
41.05 - Bid 41.40 x 400
- Ask 41.60 x 100
- Day's Range
39.92 - 41.53 - 52 Week Range
13.82 - 53.69 - Volume
263,107 - Avg. Volume
1,423,193 - Market Cap (intraday)
2.719B - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
-- - EPS (TTM)
-2.09 - Earnings Date Nov 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
54.78
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
www.tandemdiabetes.comRecent News: TNDM
View More
Performance Overview: TNDM
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TNDM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TNDM
View MoreValuation Measures
Market Cap
2.70B
Enterprise Value
2.72B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.37
Price/Book (mrq)
11.52
Enterprise Value/Revenue
3.42
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-17.15%
Return on Assets (ttm)
-9.98%
Return on Equity (ttm)
-48.48%
Revenue (ttm)
796M
Net Income Avi to Common (ttm)
-136.49M
Diluted EPS (ttm)
-2.09
Balance Sheet and Cash Flow
Total Cash (mrq)
452.42M
Total Debt/Equity (mrq)
204.00%
Levered Free Cash Flow (ttm)
-33.92M
Research Analysis: TNDM
View MoreCompany Insights: TNDM
TNDM does not have Company Insights
Research Reports: TNDM
View MoreLowering target price to $37.00
TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $37.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetTandem Earnings: Launch of Mobi Improves Growth Profile, but Moaty Competitors Keep Pressure On
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
RatingPrice TargetRaising target price to $39.00
TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $39.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetTandem Earnings: Launch of Mobi Improves Growth Profile, but Moaty Competitors Keep Pressure On
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
RatingPrice Target